SIDE-EFFECTS OF THE CATECHOL-O-METHYL-TRANSFERASE INHIBITOR RO-40-7592 IN RABBITS

被引：7

作者：

GARRIDO, JM

MENA, MA

CORREA, C

HERRARAS, O

JORGE, P

LEENDERS, K

ANTONINI, A

GUNTHER, I

PSYLLA, M

DEYEBENES, JG

机构：

[1] UNIV AUTONOMA MADRID,FDN JIMENEZ DIAZ,FAC MED,SERV NEUROL,E-28040 MADRID,SPAIN

[2] HOSP RAMON Y CAJAL,DEPT INVEST,MADRID,SPAIN

[3] PAUL SCHERRER INST,DEPT PET,VILLIGEN,SWITZERLAND

[4] FDN JIMENEZ DIAZ,SERV NEUROL,E-28040 MADRID,SPAIN

来源：

CLINICAL NEUROPHARMACOLOGY | 1994年 / 17卷 / 03期

关键词：

PARKINSONS DISEASE; COMT INHIBITORS; NOREPINEPHRINE;

D O I：

10.1097/00002826-199406000-00006

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Catechol-O-methyl-transferase inhibitors are promising drugs in Parkinson's disease since these drugs enhance levodopa effects and increase their duration. However, since these compounds block a pathway for the peripheral metabolism of catecholamines, they may also produce side effects related to elevation of catecholamines in plasma. We investigated the adverse effects of Ro 40-7592 in rabbits and the relationship of Ro 40-7592 to norepinephrine plasma levels. Intravenous administration of Ro 40-7592 in rabbits induced elevation of norepinephrine plasma levels in old animals after bolus injection of a dose three times the highest dose actually recommended to be taken orally by humans. Though Ro 40-7592 appears safe for humans, special precautions may be needed in patients with a high risk of adrenergic hyperactivity.

引用

页码：270 / 276

页数：7

共 7 条

[1]

ANTON AH, 1962, J PHARMACOL EXP THER, V138, P360

[2] EFFECTS OF COMT INHIBITORS ON STRIATAL DOPAMINE METABOLISM - A MICRODIALYSIS STUDY [J].